Client News
Okyo Pharma Limited: Grant of options -PDMR dealingLondon, March 15, 2023 – OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (“DED”) to address the significant unmet need in this multi-billion-dollar market, today announces that the board of directors of the Company (the “Board” or “Directors”), acting on a recommendation of the Remuneration Committee has awarded the following options (each to acquire one new ordinary share of no par value) (“Options”) to directors and persons discharging managerial responsibility:
|
Gary S. Jacob |
Chief Executive Officer |
5,500,000 Options |
|
Keeren Shah |
Chief Financial Officer |
6,550,000 Options |
|
Dr. Raj Patil |
Chief Scientific Officer |
15,500,000 Options |
|
Willy Simon |
Non-executive director |
400,000 Options |
|
John Brancaccio |
Non-executive director |
1,000,000 Options |
|
Bernard Denoyer |
Non-executive director |
200,000 Options |
The exercise price for all options is £0.025 per share. The options all vest in 4 equal tranches over 4 years, with the first tranche vesting on 14 March 2024, and all options have a life of ten years.
Holders of the Company’s ADS should note that for the purposes of comparison of the quantum of the awards, each ADS held represents 65 ordinary shares.
This information set out below is provided in accordance with Article 19(3) of UK MAR:
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|||||||||
|
a) |
Name |
|
||||||||
|
2 |
Reason for the notification |
|||||||||
|
a) |
Position/status |
See 1a) above |
||||||||
|
b)
|
Initial notification /Amendment |
Initial notification |
||||||||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||||
|
a) |
Name |
OKYO Pharma Limited |
||||||||
|
b) |
LEI |
213800VVN5CB56Y15A05 |
||||||||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||||||
|
a)
|
Description of the financial instrument, type of instrument
|
Ordinary Shares of no par value
|
||||||||
|
b) |
Identification code |
ISIN for OKYO Pharma Limited: GG00BD3FV870 |
||||||||
|
c) |
Nature of the transaction |
Grant of options
|
||||||||
|
d) |
Price(s) and volume(s) |
Price: £0.025 per share Volumes:
|
||||||||
|
e) |
Aggregated information – Aggregated volume – Price |
n/a
|
||||||||
|
f) |
Date of the transaction |
14 March 2023 |
||||||||
|
g) |
Place of the transaction |
Outside of a trading venue |
||||||||
Director/PDMR Dealings – 07:01:01 15 Mar 2023 – OKYO News article | London Stock Exchange
OPEN AN ACCOUNT
If you are interested in opening an account with Optiva Securities, please fill in the details on the apply button.
CLIENT AREA
Please ensure that the information you entered is accurate, and that your “Caps Lock” key is set correctly.